Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Antithrombotic therapy for transcatheter structural heart intervention.

Author information

Affiliations

  • 1. Sorbonne Université, ACTION Group, INSERM UMRS 1166, Institut de Cardiologie (AP-HP), Paris, France.
      Authors
    • Guedeney P 1
    • Montalescot G 1
    • Collet JP 1
    (3 authors)
  • 2. Quebec Heart & Lung Institute, Laval University, Quebec City, QC, Canada.
      Authors
    • Rodés-Cabau J 2
    (1 author)
  • 3. Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
      Authors
    • Ten Berg JM 3
    (1 author)
  • 4. Department of Cardiology, Bern University Hospital (Inselspital), University of Bern, Bern, Switzerland.
      Authors
    • Windecker S 4
    (1 author)
  • 5. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
      Authors
    • Angiolillo DJ 5
    (1 author)

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 01 Aug 2024, 20(16):972-986
https://doi.org/10.4244/eij-d-23-01084 PMID: 39155752 

Review

Free full text available after 19 Aug 2025

Abstract 

Percutaneous transcatheter structural heart interventions have considerably expanded within the last two decades, improving clinical outcomes and quality of life versus guideline-directed medical therapy for patients frequently ineligible for surgical treatment. Transcatheter structural heart interventions comprise valve implantation or repair and also occlusions of the patent foramen ovale, atrial septal defects and left atrial appendage. These procedures expose structural devices to arterial or venous blood flow with various rheological conditions leading to potential thrombotic complications and embolisation. Furthermore, these procedures may concern comorbid patients at high risk of both ischaemic and bleeding complications. This state-of-the-art review provides a description of the device-related thrombotic risk associated with these transcatheter structural heart interventions and of the current evidence-based guidelines regarding antithrombotic treatments. Gaps in evidence for each of the studied transcatheter interventions and the main ongoing trials are also summarised.

Full text links 

Read article at publisher's site: https://doi.org/10.4244/eij-d-23-01084

References 

Articles referenced by this article (93)

Show 10 more references (10 of 93)

Citations & impact 

This article has not been cited yet.

Impact metrics

Alternative metrics

Altmetric item for https://www.altmetric.com/details/166494116
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/166494116

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.